Addex Therapeutics Emerges From Under The Radar
Having had to retrench after a financial crisis four years ago, Swiss biotech Addex Therapeutics has been focusing on its in-house platform around allosteric modulation. CEO Tim Dyer speaks to Scrip in a video interview recorded at Biotech Showcase.
You may also be interested in...
Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.